BioMarin Pharmaceutical Inc. ( BMRN ) recently announced the completion of a phase I study, which evaluated its candidate BMN-111 in men (above 18 years) suffering from achondroplasia.
See the article here:
Pipeline Progress at BioMarin – Analyst Blog